irinotecan has been researched along with ma-1 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 7 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arigami, T; Ehi, K; Ishigami, S; Kita, Y; Kurahara, H; Matsushita, D; Mori, S; Natsugoe, S; Noda, M; Okubo, K; Sasaki, K; Uenosono, Y; Yanagita, S | 1 |
| Hara, H; Ishihara, S; Kagawa, Y; Kajiwara, T; Kawakami, H; Kotaka, M; Kuboki, Y; Makiyama, A; Masuishi, T; Morita, S; Nakajima, TE; Nakamura, M; Ojima, H; Oki, E; Ozawa, D; Shirao, K; Sugimoto, N; Sunakawa, Y; Takashima, A; Takenaka, N; Taniguchi, H; Terazawa, T; Watanabe, J; Yoshino, T | 1 |
| Benhadji, KA; Fakih, MG; George, B; Ghidini, M; Makris, L; Shitara, K; Sundar, R; Taieb, J | 1 |
| Berres, ML; Gonzalez-Carmona, M; Kehmann, L; Keitel, V; Luedde, T; Modest, DP; Mohr, R; Roderburg, C; Strassburg, C; Trautwein, C; Venerito, M; Wree, A | 1 |
| Furusawa, K; Furuse, J; Furuta, M; Hamaguchi, T; Hashimoto, I; Hayashi, K; Inokuchi, Y; Kanematsu, K; Machida, N; Maeda, S; Nagasawa, S; Notsu, A; Ogata, T; Onuma, S; Oshima, T; Suematsu, H; Watanabe, M; Yamada, T | 1 |
| Ando, M; Hamauchi, S; Honda, K; Kadowaki, S; Kawakami, T; Masuishi, T; Mori, K; Muro, K; Narita, Y; Onozawa, Y; Shirasu, H; Taniguchi, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T | 1 |
| Alberts, SR; Borad, MJ; Chakrabarti, S; Fernandez-Zapico, ME; Foster, N; Fruth, B; Hartgers, M; Hogenson, TL; Jin, Z; Mahipal, A; McWilliams, RR; Nguyen, T; Pitot, H; Qian, S; Tella, SH; Washburn, L; Wee Ma, W; Wessling, J | 1 |
5 trial(s) available for irinotecan and ma-1
| Article | Year |
|---|---|
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Frontotemporal Dementia; Humans; Irinotecan; Pyrrolidines; Rectal Neoplasms; Thymine; Trifluridine | 2023 |
Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Esophagogastric Junction; Humans; Irinotecan; Paclitaxel; Pyrrolidines; Stomach Neoplasms; Trifluridine | 2023 |
Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Frontotemporal Dementia; Gemcitabine; Humans; Irinotecan; Prospective Studies; Trifluridine | 2023 |
Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Irinotecan; Rectal Neoplasms; Trifluridine; Uracil | 2023 |
Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract; Carcinoma; Gastrointestinal Neoplasms; Humans; Irinotecan; Trifluridine | 2023 |
2 other study(ies) available for irinotecan and ma-1
| Article | Year |
|---|---|
Response Rate and Prognostic Impact of Salvage Chemotherapy after Nivolumab in Patients with Advanced Gastric Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Irinotecan; Male; Middle Aged; Nivolumab; Organoplatinum Compounds; Prognosis; Progression-Free Survival; Pyrrolidines; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Thymine | 2020 |
Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Frontotemporal Dementia; Humans; Irinotecan; Nivolumab; Stomach Neoplasms; Trifluridine; Uracil | 2023 |